Starmer’s China Visit Signals New Era in UK–China Economic Relations 
Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Australia Wine Exports Fall in 2025 as Global Drinking Declines and China Demand Weakens 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
U.S. and Taiwan Strengthen AI, Semiconductor, and Drone Cooperation at High-Level Economic Talks 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
